Panacea Journal of Medical Sciences

---

Clinical profile of hepatitis b reactivation in HBSAG-Negative and anti-HBC- Positive patients receiving anticancer chemotherapy

Full Text PDF Share on Facebook Share on Twitter

---

Original Article

Author Details : Geetha G, Shafique A, Poppy Rejoice R, Kandasamy Aliaskumar E*, Roshni Gobinath, Ramukrishnan U, Kishore Kumar R

Volume : 14, Issue : 3, Year : 2024

Article Page : 645-649

https://10.18231/j.pjms.2024.114

Suggest article by email

---

Abstract

Background: The prevalence of hepatitis B virus (HBV) reactivation in HBsAg-negative and anti-HBc-positive individuals following chemotherapy for various cancers remains unknown. This research focused on investigating the prevalence and clinical features of HBV reactivation in HBsAg negative and anti –HBc-positive patients.
Materials and Methods: This is prospective research involving cancer patients on chemotherapy who develop hepatitis B surface antigen positivity in a previously hepatitis B surface antigen-negative and hepatitis core antibody-positive patient. The analysis included 40 patients and followed up for 8 months.
Results: Among 40 patients, mostly 97.5% had a solid tumor and 3(2.5%)patients had haematological malignancy. The majority (42.5%) received anthracycline-based therapy and others received cisplatinum plus 5 fluorouracil therapy, platinum-based therapy and steroid therapy.
Conclusion: In our study, almost all patients with HBsAg negative and HBcAb positive patients undergoing chemotherapy for solid tumor shows HBV reactivation. So antivirals may be considered in HBsAg negative and HBcAb positive patients undergoing chemotherapy for solid tumor regardless of HBV DNA level and HBsAg seroconversion.
 

Keywords: Chemotherapy, Hepatitis B virus reactivation, Prophylactic antiviral therapy, Solid tumours

How to cite : Geetha G, Shafique A, Poppy Rejoice R, Kandasamy Aliaskumar E, Gobinath R, Ramukrishnan U, Kishore Kumar R, Clinical profile of hepatitis b reactivation in HBSAG-Negative and anti-HBC- Positive patients receiving anticancer chemotherapy. Panacea J Med Sci 2024;14(3):645-649

Copyright © 2024 by author(s) and Panacea J Med Sci. This is an Open Access article distributed under the terms of the Creative Commons Attribution 4.0 International License (creativecommons.org)